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Windows file sharing Server Message Block protocol was 
developed to integrate with OSSEC, allowing client free FIM 
for Windows systems.  
OSSEC was installed onto an in-house virtualised server and 
configured to perform nightly checks on a non-clinical test 
infrastructure, monitoring both workstations and file servers 
with read-only permissions. The resulting checksums were 
independently verified. Subsequent file changes are recorded 
in a robust database management system (PostgreSQL) for 
audit, with alerts sent via the hospital email to provide a 
convenient method of informing the TPS team of events.  
Results: OSSEC calculated MD5 and SHA1 checksums for of all 
files specified for inclusion. Alterations to files subsequently 
were notified to the designated email addresses. The 
program did not cause any change to the system being 
monitored. Following successful testing, OSSEC has been in 
routine use for 12 months and has sent nearly 1400 change 
notifications. 99.8% of these were either planned changes to 
configuration files, alterations to user preferences or updates 
to log files, used to test OSSEC functionality. A single 
unplanned change to critical beam data was detected. In this 
case, the change caused the TPS to cease functioning. OSSEC 
provided a list of alterations, which could be used to revert 
the system to an operational state. 
Conclusions: OSSEC can be implemented in a multi-vendor, 
multi-platform radiotherapy department to perform FIM, in 
an integrated and unified manner. Monitoring the integrity of 
executable files and the data sets on which they depend on, 
provides a robust method of assuring software remains in the 
same state as it was commissioned, with a minimum amount 
of human intervention. 
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Purpose/Objective: Volumetric modulated arc therapy 
(VMAT) is one of the methods of delivering stereotactic body 
radiation therapy (SBRT) for lung tumors. VMAT allows fast 
delivery. Nevertheless is thought to increase the lung volume 
dose, especially in low dose area. Therefore we assessed the 
lung volume receiving 5 and 20 Gy delivered with VMAT plans 
and also dose for contralateral lung. 
Materials and Methods: We collected 49 VMAT- SBRT plans 
introduced for patients with lung tumors. Of the patients, 7 
were female, 42 were male. Three patients had two 
ipsilateral lung tumors. Three patients undergone 
pulmonectomy. Based on 4D CT there were outlined 
structures: GTV, ITV, PTV (ITV+5mm) and organs at risk.  
Every plan was created with two partial arcs, in order to 
decrease dose to contralateral lung. Lung volume receiving 5 
and 20 and separately V5 for contralateral were assessed. No 
GTV subtraction from lung volume were used. According to 
RTOG SBRT trials dose constrains were V5-50%, V20-20%. 
Results: Mean GTV volume was 17,6 cm3 (range 0,8-89 cm3 , 
median 11,6 cm3 ), ITV 26,9 cm3 (range 09-159,2 cm3 , median 
20,2 cm3), PTV 65,9 cm3 (range 6,5-274 cm3 , median 48,3 
cm3). The mean volume of lung receiving more than 20 Gy 
was 7,2% (range 1,1-22,8% , median 6,1%) and more than 5 Gy 
was 19,2% (range 4,3-47,1% , median 18,6%). The mean 
contralateral lung V5 was 4,5% (range 0-26,2% , median 1,6%). 
Beside one patient lung dose constrains were easily archived 
and the dose to contralateral lung was highly limited. 
Conclusions: Two partial arcs VMAT for SBRT for lung tumors 
allow creating save plan in addition of lung tissue. Even in 
low dose area the VMAT plan is acceptable. This method also 
protect contralateral lung. 
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Purpose/Objective: Thoracic re-irradiation is commonly 
found in clinical practice as a considerable number of 
patients with primary or metastatic lung lesions require 
repeat treatments to the thorax. Stereotactic body radiation 
therapy (SBRT) is an efficient modality for repeat treatments 
because it allows for delivery of high radiation dose to the 
target while minimizing the dose to the surrounding tissue. 
This case study regards a 75-year-old male patient, known for 
right lung cancer in complete remission, treated in 2011 with 
60 Gy (30x2 Gy) including mediastinum. In 2013 the patient is 
treated for pleural relapse on the right side with 48 Gy (8x6 
Gy). One year later in 2014, the patient needed treatment 
for a left lung cancer with 30 Gy (5x6 Gy). How to plan and 
evaluate the re-irradiation in this clinical situation? Which 
OAR will be the clinical limit? 
Materials and Methods: For SBRT planning (2014), the PTV 
was defined in a free breathing CT simulation, based on ITV 
(internal target volume) strategy. SBRT treatment plans were 
generated in Tomotherapy treatment planning system (VoLo, 
Accuray) to deliver the prescribed dose to the PTV of 30 Gy 
in 5 fractions. To estimate composite mean/max dose we 
used Velocity AI software, the SBRT dose was converted to 2 
Gy equivalent using the linear-quadratic model (EQD2) tool, 
(α/β = 3 Gy) for lung, heart, esophagus and bronchus, (α/β = 
2 Gy) for the spinal cord and (α/β = 10 Gy) for the PTV. For 
the plan comparison, dosimetric parameters for the analyze 
included PTV coverage, mean dose to ipsilateral lung, mean 
dose to both lungs, volume receiving 20 Gy (V20) of both 
lungs, max dose for esophagus, max dose for spinal cord, max 
dose for bronchus and max dose to the heart.  
Results: In a first analysis, we estimate the esophagus max 
dose in EQD2 of 82.21 Gy on the first composite plan, non 
acceptable in clinical practice. We then re-planned using a 
PRV (planning risk volume) for esophagus and re-optimized. 
The PTV D95% for the first plan is 28.5 Gy vs 29 Gy on the 
second plan. When we compare the first and second 
composite plans EQD2, we obtained a mean dose to both 
lungs of 10.57 Gy vs. 10.97 Gy; V20 Gy of 14% vs. 14.8%; 
esophagus max of 64.8 Gy vs. 82.21 Gy, spinal cord max dose 
of 30.79 Gy vs. 29.41 Gy; bronchus max dose of 81.12 Gy vs. 
94.13 Gy and for heart max dose of 44.04 Gy vs. 48.72 Gy. 
Conclusions: This case underline the new information 
obtained from tools such as image registration and scaled 
dose volume using biological equivalent transformation. The 
technique allowed us to understand easier which OAR will be 
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limiting and how to optimize the plan. Without this 
approach, there was an increase risk of severe, even fatal 
esophagus toxicity for the patient. 
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Purpose/Objective: In England in 2012/2013, there was a 
strong Government drive to increase the availability of 
IMRT/VMAT treatment for appropriate patient groups. Up to 
September 2013, prostate and seminal vesicle patients (PSV) 
at this centre were treated with a 3 field forward planned 
IMRT technique (fpIMRT) using 10MV photons (with target and 
OAR doses based on the CHHiP trial using a 3 dose level 
target PTV1, 2 and 3). This was replaced with a 6MV single 
arc VMAT technique. In both cases, treatment delivery was 
with Elekta Synergy accelerators fitted with MLCi (1cm leaf 
width). This investigation looked at the organ at risk (OAR) 
doses achieved using both techniques. In introducing this new 
technique, the minimum target dose to PTV1 (PSV + a 
uniform margin of 1cm) was also increased in line with 
another UK department who provided VMAT implementation 
mentoring. This audit assessed the effect of the treatment 
technique change along with PTV1 dose escalation and 
identified whether the acute side effects seen during 
treatment were affected by this technique and dose change. 
Materials and Methods: Philips Pinnacle V9.8 is routinely 
used to contour and plan all PSV patients. DVH analysis was 
performed to extract OAR doses and PTV doses for 39 
patients who were planned using the fpIMRT technique and 
49 patients planned using the VMAT technique. Microsoft 
Excel 2010 was used to collate and analyse the data. The 
RTOG scoring system was used during treatment to assess 6 
common acute side effects for this group of patients. 
Results: All dose constraints were met consistently met using 
a forward planned technique. However the introduction of 
VMAT planning allowed an escalation to the achievable PTV1 
minimum dose within those same dose constraints. The RTOG 
scores during treatment for six common acute side effects for 
this group of patients showed that whilst the difference in 
technique has not decreased the side effects seen by a 
statistically significant amount, the average score for each 
side effect were lower for the patients treated with VMAT, 
even with the higher dose to PTV1. 
The low dose bath effect to the rectum of the VMAT planning 
technique is evident in the analysis of the dose constraints, 
with the average V30Gy at 76.2% and the average V40Gy at 
64.6%, compared with V30Gy: 55.8%, V40Gy: 43.4% for 
fpIMRT. These dose constraints were not classified as 
mandatory in the CHHiP clinical trial or in this department's 
clinical protocol. The mandatory high dose (65Gy, 70Gy, 
74Gy) constraints demonstrate a reduction in the amount of 
rectum within these dose regions of the prostate treatment 
with the implementation of VMAT. 
 
Conclusions: Implementation of a VMAT technique for the 
treatment of PSV has resulted in an increase of dose 
uniformity of the PTVs by increasing the achievable minimum 
PTV1 dose and reducing the high dose level received by the 
rectum. Further work will investigate whether there is scope 
within those same OAR constraints to escalate PTV doses 
further if clinically rquired. 
   
EP-1652   
Feasibility, tolerance and toxicity of adjuvant vaginal 
brachytherapy in endometrial cancer 
A. Grillo1, M. Gueci1, F. Sciumè1, G. Evangelista1, A. Lo Casto2 
1Ospedale Civico Palermo, Radiotherapy, Palermo, Italy  
2Policlinico Universitario P. Giaccone, Radiology, Palermo, 
Italy  
 
Purpose/Objective:  tolerance and toxicity of adiuvant 
exclusive vaginal High Dose Rate Brachytherapy (HDR_BT) in 
patients with endometrial cancer. 
Materials and Methods: A total of 30 patients (pts), median 
age 70 years old, were treated by postoperative HDR vaginal 
cuff Brachytherapy. Patients underwent hysterecomy for 
endometrial cancer. Staging and grading according FIGO were 
8-IA, 18 IB, 3 II, 1-IIIA; 2-G1, 18-G2, 10-G3. HDR-BRT was 
performed using vaginal cylindrical applicators applied to the 
patients who received five fractions of 600cGy to a total dose 
of 3000 cGy prescribed to the 0.5 from the applicator's 
surface. Computed Tomography (CT) simulation was 
performed with CT slices thickness of 5 mm. Proximal 3-3.5 
cm of the vagina were treated. Bowels are more than bladder 
very radiosensitive and so to prevent bowels toxicity, all 
patients were asked to consume from 250 ml to 400 ml of 
water 30 minutes before CT scan and before treatment and 
empty rectum by means a selfie applied rectal enema. Acute 
and late Gastrointestinal (GI) and Genitourinary (GU) 
toxicities were investigate according RTOG Toxicity scale. 
